Recent guidelines of using SGLT 2 inhibitiors
Reading File
Searching PubMed
SGLT2 inhibitors guidelines recommendations
Searching the Web
SGLT2 inhibitors guidelines 2024 2025 recommendations heart failure CKD diabetes
Finding Sources
Reading Article
PMID: 38639546
Reading Article
PMID: 40063957
Reading File
Finding Sources
Reading Article
PMID: 38991584
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
SGLT2 Inhibitors: Recent Guidelines (2024-2026)
SGLT2 inhibitors (gliflozins) have undergone a dramatic expansion in their recommended indications over the past few years. They are no longer simply diabetes drugs - they are now considered foundational cardiorenal-metabolic therapy.
Available Agents & Doses
| Drug | Doses Available | Key Indications |
|---|---|---|
| Dapagliflozin (Farxiga) | 5 mg, 10 mg | T2DM, HFrEF, HFpEF (LVEF >40%), CKD |
| Empagliflozin (Jardiance) | 10 mg, 25 mg | T2DM, HFrEF, HFpEF, CKD |
| Canagliflozin (Invokana) | 100 mg, 300 mg | T2DM, CKD, CV risk reduction |
| Ertugliflozin (Steglatro) | 5 mg, 15 mg | T2DM |
All are once-daily oral agents with ~60-80% bioavailability, unaffected by food. Half-life ~12 hours. Metabolized by glucuronidation; inactive metabolites renally excreted.
1. Type 2 Diabetes (T2DM)
ACP 2024 Guideline (Ann Intern Med, 2024 - PMID 38639546):
- Strong recommendation (high-certainty evidence): Add an SGLT2 inhibitor or GLP-1 agonist to metformin + lifestyle modification when glycemic targets are not met.
- SGLT2 inhibitors are specifically preferred to:
- Reduce all-cause mortality
- Reduce major adverse cardiovascular events (MACE)
- Slow CKD progression
- Reduce hospitalization for heart failure
- DPP-4 inhibitors are recommended against as second-line agents for morbidity/mortality reduction.
ADA Standards of Care (ongoing):
- SGLT2 inhibitors recommended as preferred add-on for patients with T2DM and established ASCVD, HF, or CKD - regardless of HbA1c level.
- Use an SGLT2i with eGFR ≥20 mL/min/1.73 m² + uACR ≥300 mg/g to reduce CKD progression and CV events.
2. Heart Failure (HF)
Guidelines from both US (ACC/AHA) and Europe (ESC) now recommend SGLT2 inhibitors as foundational therapy regardless of ejection fraction or diabetes status - Harrison's Principles of Internal Medicine, 22nd Ed.
HFrEF (LVEF ≤40%)
- Dapagliflozin and empagliflozin: Both are Class I recommendations added to optimal background therapy (ACEi/ARNI + beta-blocker + MRA).
- Key trials: DAPA-HF (dapagliflozin) and EMPEROR-REDUCED (empagliflozin) - both showed reduced CV mortality and HF hospitalization in patients with and without diabetes.
HFpEF / HFmEF (LVEF >40%)
- SGLT2 inhibitors are now endorsed as the only class with clear mortality and morbidity benefit in HFpEF.
- EMPEROR-Preserved trial: empagliflozin reduced CV death or HF hospitalization by 21% (HR 0.79; 95% CI 0.69-0.90) and recurrent HF hospitalizations by 27%, with no modification by diabetes status.
- DELIVER trial: dapagliflozin confirmed similar benefits in LVEF >40%.
- Practical note: SGLT2 inhibitors may allow titration/reduction of loop diuretics due to their natriuretic effect. - Fuster and Hurst's The Heart, 15th Ed.
Practical HF Initiation Tips
- In patients on sulfonylureas or insulin with well-controlled diabetes: reduce/stop diuretic or sulfonylurea/insulin dose before starting SGLT2i to avoid hypovolemia/hypoglycemia.
- If hypervolemic or poorly controlled: no pre-adjustment needed. - Lippincott Illustrated Reviews Pharmacology
3. Chronic Kidney Disease (CKD)
KDIGO 2024 Clinical Practice Guideline (Ann Intern Med, 2025 - PMID 40063957):
| CKD Stage | eGFR | Canagliflozin | Dapagliflozin |
|---|---|---|---|
| Stage 3a | 45-59 | 100-300 mg/day | 10 mg/day |
| Stage 3b | 30-44 | 100 mg/day (max) | 10 mg/day |
| Stage 4 | 15-29 | Do not initiate; continue 100 mg if tolerated | 10 mg/day |
| Stage 5 / Dialysis | <15 | Generally avoid initiation | Generally avoid |
Key KDIGO 2024 recommendations:
- Treat CKD patients with T2DM and eGFR ≥20 mL/min/1.73 m² with an SGLT2 inhibitor (Grade 1A).
- Benefits extend to non-diabetic CKD - DAPA-CKD trial showed consistent reduction in CKD progression and death regardless of diabetes status, including patients with chronic glomerulonephritides. - Comprehensive Clinical Nephrology, 7th Ed.
- Note: Glycemic efficacy is reduced as eGFR falls, but renal and cardiovascular protective effects are preserved down to eGFR 20-25 mL/min/1.73 m².
Key trials driving CKD recommendations:
- CREDENCE: Canagliflozin in T2DM + CKD (eGFR 30-90) - reduced kidney failure, death from kidney/CV causes.
- DAPA-CKD: Dapagliflozin in CKD with and without T2DM - significant reduction in eGFR decline, ESKD, and mortality.
- EMPA-KIDNEY: Empagliflozin in CKD eGFR 20-45 with uACR ≥200 - confirmed renoprotective benefits.
4. Perioperative Management (2025 Consensus)
PMID 39781571 (Anaesthesia, 2025 - multidisciplinary UK consensus):
- SGLT2 inhibitors should generally be withheld 3-4 days before elective surgery due to risk of euglycemic DKA.
- Resume when patient is eating and drinking normally and surgical stress has resolved.
5. Combined SGLT2i + GLP-1RA Use
Lancet Diabetes Endocrinol, 2024 (SMART-C meta-analysis - PMID 38991584):
- SGLT2 inhibitors provide independent, additive cardiovascular and kidney benefits even when combined with GLP-1 receptor agonists.
- Effects on MACE (HR ~0.90), HF hospitalization/CV death (HR ~0.78), and CKD progression (HR ~0.67) were consistent regardless of background GLP-1RA use.
- This supports combination use of both drug classes per current guidelines.
Adverse Effects & Contraindications
| Effect | Notes |
|---|---|
| Genital mycotic infections | 3-5% increase; most common in women |
| Urinary tract infections | ~2% increase |
| Volume depletion / hypotension | Especially in elderly; monitor diuretics |
| Euglycemic DKA | Rare but serious; risk with illness, fasting, surgery - withhold perioperatively |
| Fournier gangrene | Rare necrotizing fasciitis of perineum |
| Initial eGFR dip | Transient, functional; resolves; does NOT indicate harm |
| Hypoglycemia | Not from SGLT2i alone; risk increases with concurrent sulfonylurea/insulin |
| Bone fractures | Early canagliflozin signals not confirmed in further studies |
Contraindications: eGFR <20-25 mL/min/1.73 m² (for initiation), recurrent UTIs, T1DM (relative), pregnancy and breastfeeding (avoid - insufficient safety data). - Goodman & Gilman's Pharmacological Basis of Therapeutics
Summary of Guideline-Endorsed Indications
| Indication | Agent(s) | Diabetes Required? |
|---|---|---|
| T2DM + inadequate glycemic control | Any SGLT2i | Yes |
| T2DM + ASCVD/high CV risk | Empagliflozin, canagliflozin, dapagliflozin | Yes |
| HFrEF (any EF ≤40%) | Dapagliflozin, empagliflozin | No |
| HFpEF/HFmEF (EF >40%) | Empagliflozin, dapagliflozin | No |
| CKD (eGFR ≥20, uACR ≥200-300) | Dapagliflozin, canagliflozin, empagliflozin | No |
Key principle: The cardiorenal benefits of SGLT2 inhibitors are largely independent of glucose lowering - they work through hemodynamic, tubuloglomerular feedback, and possibly mitochondrial/NHE-inhibition mechanisms. This is why benefits extend to non-diabetic patients.
Sources: Harrison's Principles of Internal Medicine 22E (2025); Fuster and Hurst's The Heart, 15th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics; Comprehensive Clinical Nephrology 7th Ed.; ACP 2024 Guideline (PMID 38639546); KDIGO 2024 CKD Guideline Synopsis (PMID 40063957); SMART-C Meta-Analysis, Lancet Diabetes Endocrinol 2024 (PMID 38991584); Perioperative Consensus, Anaesthesia 2025 (PMID 39781571)
This is a shared conversation. Sign in to Orris to start your own chat.